Bold Therapeutics Inc.

04/28/2025

Today kicks off an exciting week at .

Bold Therapeutics is excited to present our late-breaking data on BOLD-100's unique ability to mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN). Building on our exciting data read-out last year, showing improved efficacy in combination with FOLFOX in GI cancers, this exciting discovery further demonstrates BOLD-100's potential as a transformative therapy in early-line colorectal cancer, biliary tract cancer, and other solid tumour indications!

Please join our Executive Vice President, Jim Pankovich, Senior Director of Preclinical Development, Mark Bazett, and Senior Scientist, Ashish Kumar PhD, on Wednesday for our poster presentation.

Session: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Date & Time: April 30, 2025, from 9:00 AM to 12:00 PM
Location: Poster Section 51, Poster Board #14
Poster Code:
Poster Title: “Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model”

https://tinyurl.com/mryuzck5

06/05/2024

Bold is proud to announce our positive Phase 2 results for BOLD-100 at ASCO 2024.

03/20/2024

Proud to have represented Bold Therapeutics and Canadian biopharma innovation at BIO-Europe Spring 2024 in Barcelona, presenting our remarkable Phase 2 data in advanced metastatic colorectal, biliary tract and gastric cancers to potential investors and strategic partners.

My quote of the week: 'Oh - you're the metal drug guys, right? Heard you're rocking it!'

04/18/2023

Bold Therapeutics is excited to share interim Phase 2 data for BOLD-100 in the treatment of advanced colorectal cancer, one of the most difficult-to-treat solid tumour indications. Credit to the dedicated Bold Therapeutics team, our clinical investigators and our patients for their contribution to this important milestone event for our company. We also wish to thank the Canadian government for their ongoing support of our development efforts.

See here for more details: https://tinyurl.com/496xbxsm
Visit our website at bold-therapeutics.com.

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim...

10/14/2022

Bold Therapeutics is happy to announce that we will be attending the 2022 Conference in Leipzig, Germany from October 24 - 26! We also look forward to presenting at the virtual segment taking place November 2 - 4.

For more information, please visit https://lnkd.in/e2A9hV6r

06/24/2022

Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 from the 2022 ASCO General Meeting in metastatic colorectal cancer, one of the most difficult-to-treat solid tumour indications. If this data can be replicated in a larger sample size, it would dramatically improve outcomes for these patients.

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research...

05/11/2022

Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.

/PRNewswire/ -- Bold Therapeutics will be presenting at Bio Korea 2022, the largest Life Sciences international convention in Korea, on May 11 to 13, 2022 in...

04/06/2022

Bold Therapeutics is excited to share further information elucidating the mechanism-of-action of BOLD-100 and demonstrating its unique potential as an anticancer agent.

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in...

04/04/2022

We're excited to share our 2nd Place win at the recent 2022 Innovator's Pitch Challenge on March 22-24, beating out many larger and more established life sciences companies and drawing attention to the rising tide of Canadian biopharma.

/PRNewswire/ -- Bold Therapeutics, a Vancouver-based clinical-stage biopharmaceutical company, is excited to announce that they placed second in the...

03/01/2022

Since its founding in mid-2018, Bold Therapeutics has made rapid and efficient progress. Today, Bold Therapeutics' BOLD-100 advances into a global Phase 2 trial in the treatment of advanced GI cancers, among the most difficult-to-treat and refractory solid tumours with a mean survival time of only 5-7 months. We are optimistic that outcomes will be meaningfully improved by adding BOLD-100 to patients' existing treatment regimens. We look forward to interim Phase 2 data by year-end 2022.

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they have successfully completed the Phase 1b (dose-escalation)...

01/13/2022

Bold is pleased to announce that Hana Pharm has extended our South Korean Option Agreement for BOLD-100.

/PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement...